Skip to main content
CADL
NASDAQ Life Sciences

Candel Therapeutics Formalizes $100M Public Offering, Extends Cash Runway to Q1 2028

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
8
Price
$5.1
Mkt Cap
$280.256M
52W Low
$4.25
52W High
$13.68
52W Position info
20% above low
Off High info
63% below high
Rel. Volume info
8.7× avg
Market data snapshot near publication time

CADL sits 20% above its 52-week low of $4.25 on elevated volume (8.7× avg).

Summary

Candel Therapeutics formalized its $100 million public offering of common stock, priced at a premium to the current market, which is expected to extend the company's cash runway into the first quarter of 2028.


Key Events · Financing and Capital Events · CADL

  • Underwriting Agreement Formalized

    Candel Therapeutics entered into an underwriting agreement on February 19, 2026, for a public offering of common stock, formalizing the terms of the previously announced offering.

  • Public Offering Details

    The company agreed to sell 18,348,624 shares of common stock at a public offering price of $5.45 per share, with underwriters having a 30-day option to purchase an additional 2,752,293 shares.

  • Significant Capital Raise

    The offering is expected to generate approximately $93.5 million in net proceeds from the base offering, potentially increasing to $107.6 million if the underwriters' option is fully exercised.

  • Cash Runway Extended

    The net proceeds are anticipated to fund the company's operating expenses and capital expenditure requirements into the first quarter of 2028, providing critical financial stability for a clinical-stage biotech.


Analysis · CADL · Life Sciences

This 8-K formalizes the underwriting agreement for the previously announced $100 million public offering of common stock. While the offering is significantly dilutive for a company of this market capitalization, it was successfully priced at $5.45 per share, which is a premium to the current stock price of $5.10, indicating strong institutional demand. Crucially, the net proceeds of approximately $93.5 million are projected to extend the company's cash runway into the first quarter of 2028. This funding is vital for a clinical-stage biopharmaceutical company, providing essential capital for the development and commercialization of its lead product candidate, CAN-2409, and significantly reduces near-term financing risk.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CADL was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $280.3M. The 52-week trading range was $4.25 to $13.68. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CADL - Latest Insights

CADL
Nov 13, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
8
Price at Filing: $5.11
Real-time Price: $6.44 info
Change: +$1.33 (+26%) info
Market Cap: $492.78M info
CADL
Nov 12, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.44 info
Change: -$1.95 (-23%) info
Market Cap: $492.78M info
CADL
Nov 12, 2026, 4:05 PM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $8.39
Real-time Price: $6.44 info
Change: -$1.95 (-23%) info
Market Cap: $492.78M info
CADL
Oct 01, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.40
Real-time Price: $6.44 info
Change: -$3.96 (-38%) info
Market Cap: $492.78M info
CADL
Sep 30, 2026, 8:05 AM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $10.96
Real-time Price: $6.44 info
Change: -$4.52 (-41%) info
Market Cap: $492.78M info